Published in:
Open Access
01-02-2011 | Poster presentation
Safety, pharmacokinetics, and pharmacodynamics of 4-hour intravenous infusion of eritoran tetrasodium in healthy Japanese and Caucasian males
Authors:
Y Okubo, N Aikawa, M Lynn, DP Rossignol, YN Wong, E Schuck, Y Kitahara, T Nakano, O Sivak, KM Wasan, C Nagy
Published in:
Critical Care
|
Special Issue 1/2011
Login to get access
Excerpt
Activation of TLR4 signaling by endotoxin is believed to be a primary mediator of sepsis and septic shock, via excessive production of cytokines and proinflammatory mediators [
1]. Eritoran tetrasodium (hereafter eritoran), a synthetic analog of the endotoxin constituent lipid A, binds to the TLR4/MD-2 complex and thereby blocks the interaction of endotoxin with TLR4 [
2]. Eritoran is being investigated for the treatment of severe sepsis [
3]. We report results of a study conducted to assess the single-dose safety and tolerability, as well as pharmacokinetics and pharmacodynamics, of eritoran infusion in Japanese and Caucasian healthy adult males. …